BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27268915)

  • 1. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
    He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
    Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
    Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
    Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.
    Singh AV; Franke AA; Blackburn GL; Zhou JR
    Cancer Res; 2006 Feb; 66(3):1851-8. PubMed ID: 16452247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
    Ke K; Li H; Yao H; Shi XN; Dong C; Zhu Y; Liu X; Li L; Leung KS; Wong MH; Liu XD; Kung HF; Lin MC
    Chem Biol Drug Des; 2017 Apr; 89(4):505-513. PubMed ID: 27664399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
    Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
    Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
    Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
    Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
    Su SJ; Chow NH; Kung ML; Hung TC; Chang KL
    Nutr Cancer; 2003; 45(1):113-23. PubMed ID: 12791511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
    Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
    Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways.
    Chen F; Chen X; Yang D; Che X; Wang J; Li X; Zhang Z; Wang Q; Zheng W; Wang L; Wang X; Song X
    Oncol Rep; 2016 Jul; 36(1):165-72. PubMed ID: 27177091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
    Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
    J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis.
    Zhou JR; Mukherjee P; Gugger ET; Tanaka T; Blackburn GL; Clinton SK
    Cancer Res; 1998 Nov; 58(22):5231-8. PubMed ID: 9823337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade.
    Hua F; Li CH; Chen XG; Liu XP
    Int J Mol Med; 2018 Jun; 41(6):3485-3492. PubMed ID: 29512690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer.
    Su SJ; Yeh TM; Lei HY; Chow NH
    Clin Cancer Res; 2000 Jan; 6(1):230-6. PubMed ID: 10656454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
    Ceci C; Tentori L; Atzori MG; Lacal PM; Bonanno E; Scimeca M; Cicconi R; Mattei M; de Martino MG; Vespasiani G; Miano R; Graziani G
    Nutrients; 2016 Nov; 8(11):. PubMed ID: 27879653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.
    Hadari Y; Schlessinger J
    J Clin Invest; 2009 May; 119(5):1077-9. PubMed ID: 19422094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer.
    Liao X; Chen J; Liu Y; He A; Wu J; Cheng J; Zhang X; Lv Z; Wang F; Mei H
    Cancer Biomark; 2018 Feb; 21(2):277-285. PubMed ID: 29226855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.